BioLineRx Ltd. Receives Notice of Allowance From USPTO for Patent Covering BL-1020 Drug for Treatment of Schizophrenia  
4/5/2011 10:49:21 AM

JERUSALEM, April 4, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application covering the BL-1020 drug and its use for the treatment of schizophrenia. This patent, when formally issued, will be valid until September 2022 and may be eligible for a patent term extension of up to five years.